Abstract
Alzheimer’s and Parkinson’s diseases are prevalent neurodegenerative disorders worldwide, which are essentially related to aging. Within the remarkable era of nanomedicine, nowadays several delivery systems have been suggested to improve the treatment of these disorders, namely, liposomes, micelles, nanoparticles (polymeric, lipid, metallic and inorganic), exosomes, dendrimers and fullerenes. The advantage that has been claimed to these delivery systems is that they facilitate the passage of drugs through the blood brain barrier (BBB), enabling targeting before body degradation, and increasing therapeutic efficacy, comparied to conventional pharmaceutical dosage forms.
This review article provides a state of the art regarding the drug delivery systems that have been studied for the treatment of Alzheimer’s and Parkinson’s diseases. It begins with a brief description of the central nervous system (CNS) and the mechanisms involved in the development of these diseases. Later, some examples of drugs used in the treatment of these neurodegenerative diseases are presented, which are currently available in conventional pharmaceutical dosage forms, and in new drug delivery systems that are under development.
Keywords: Alzheimer's disease, Parkinson’s disease, Liposomes, Micelles, Nanoparticles, Exosomes, Dendrimers, Fullerenes.
Current Medicinal Chemistry
Title:Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems
Volume: 23 Issue: 31
Author(s): S. Cunha, M. H. Amaral, J. M. Sousa Lobo and A. C. Silva
Affiliation:
Keywords: Alzheimer's disease, Parkinson’s disease, Liposomes, Micelles, Nanoparticles, Exosomes, Dendrimers, Fullerenes.
Abstract: Alzheimer’s and Parkinson’s diseases are prevalent neurodegenerative disorders worldwide, which are essentially related to aging. Within the remarkable era of nanomedicine, nowadays several delivery systems have been suggested to improve the treatment of these disorders, namely, liposomes, micelles, nanoparticles (polymeric, lipid, metallic and inorganic), exosomes, dendrimers and fullerenes. The advantage that has been claimed to these delivery systems is that they facilitate the passage of drugs through the blood brain barrier (BBB), enabling targeting before body degradation, and increasing therapeutic efficacy, comparied to conventional pharmaceutical dosage forms.
This review article provides a state of the art regarding the drug delivery systems that have been studied for the treatment of Alzheimer’s and Parkinson’s diseases. It begins with a brief description of the central nervous system (CNS) and the mechanisms involved in the development of these diseases. Later, some examples of drugs used in the treatment of these neurodegenerative diseases are presented, which are currently available in conventional pharmaceutical dosage forms, and in new drug delivery systems that are under development.
Export Options
About this article
Cite this article as:
Cunha S., Amaral H. M., Lobo M. Sousa J. and Silva C. A., Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems, Current Medicinal Chemistry 2016; 23 (31) . https://dx.doi.org/10.2174/0929867323666160824162401
DOI https://dx.doi.org/10.2174/0929867323666160824162401 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Post-stroke Movement Disorders: Clinical Manifestations and Pharmacological Management
Current Neuropharmacology Current Treatment Concepts of Philadelphia-Negative MPN
Current Cancer Drug Targets Cardiovascular Disease: A Target for the Pharmacological Effects of Quercetin
Current Topics in Medicinal Chemistry Neuroprotection by Alpha 2-Adrenergic Agonists in Cerebral Ischemia
Current Neuropharmacology Isometric Handgrip Effects on Hypertension
Current Hypertension Reviews Usefulness of Real-Time PCR for the Diagnosis of Sepsis in ICU-Acquired Infections
Infectious Disorders - Drug Targets Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia
Current Vascular Pharmacology Microbial Efflux Pump Inhibition: Tactics and Strategies
Current Pharmaceutical Design Renin-angiotensin System Blockade at the Level of the Angiotensin Converting Enzyme or the Angiotensin Type-1 Receptor: Similarities and Differences
Current Topics in Medicinal Chemistry Beneficial Extracardiac Effects of Cardiovascular Medications
Current Cardiology Reviews Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme
Current Medicinal Chemistry Monoamine Oxidase-B (MAO-B) Inhibitors in the Treatment of Alzheimer’s and Parkinson’s Disease
Current Medicinal Chemistry Treating and Preventing No Reflow in the Cardiac Catheterization Laboratory
Current Cardiology Reviews Contractile Mechanisms in Diabetes-Related Erectile Dysfunction
Current Pharmaceutical Design Characteristics Other than the Diagnostic Criteria Associated with Metabolic Syndrome: An Overview
Current Vascular Pharmacology Cerebral Artery Signal Transduction Mechanisms: Developmental Changes in Dynamics and Ca<sup>2+</sup> Sensitivity
Current Vascular Pharmacology Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology New Developments in Systemic Therapy for Hepatocellular Carcinoma
Current Cancer Therapy Reviews Psychiatric Disorders Associated with FXTAS
Current Psychiatry Reviews Neurologic and Cardiovascular Complications in Pediatric Life Threatening Imipramine Poisoning
Current Drug Safety